Filing Flows › Jazz Pharmaceuticals (JAZZ) › Q3 2025
Jazz Pharmaceuticals (JAZZ) Q3 2025 earnings results (third quarter 2025)
10-Q filed Nov 5, 2025
Jazz Pharmaceuticals (JAZZ) reported revenue of $1.1B for the third quarter 2025 (Q3 2025), +7% from a year earlier and +8% from the quarter before. Operating margin was 5.1%, net earnings $251M (22.3% of revenue).
Jazz Pharmaceuticals, Q3 2025: revenue $1.1B (+7% year over year), operating margin 5.1%, net earnings $251M, operating cash flow $475M. The chart follows the revenue to costs, profit and cash.
| Q3 2025 | Amount | Q/Q | Y/Y |
|---|---|---|---|
| Revenue | $1.1B | +8% | +7% |
| Operating profit | $57.5M | — | -78% |
| Net earnings | $251M | — | +17% |
| Operating cash flow | $475M | +435% | +19% |
| Free cash flow | $460M | +505% | +18% |
What changed
Revenue was $1.1B in Q3 2025, up 7% year over year and up 8% from the previous quarter. Xywav was the largest line at 38% of revenue. Xywav added $0.04B year over year (up 11%), 60% of the total change. Defitelio/defibrotide declined 21%.
Operating profit was $0.06B, a 5.1% margin (down 19.6 points year over year). Operating profit fell $0.20B even though revenue rose $0.07B versus a year earlier, so costs grew faster than sales. Total costs grew 34% against revenue growth of 7%. The fastest-growing cost line was SG&A (+63%). Net earnings were $0.25B, up 17% year over year. The tax line was a benefit of $0.24B on pre-tax earnings of $0.01B.
Operating cash flow was $0.47B (up 19% year over year), 189% of net earnings. Non-cash charges added back $0.18B of depreciation and amortization and $0.09B of share-based compensation. Working capital and other items used $0.04B. Capital expenditures of $0.02B left free cash flow of $0.46B.
Questions
What was Jazz Pharmaceuticals' revenue in the third quarter 2025?
Jazz Pharmaceuticals (JAZZ) reported revenue of $1.1B for the third quarter 2025 (Q3 2025), +7% from a year earlier and +8% from the quarter before.
Was Jazz Pharmaceuticals profitable in the third quarter 2025?
Operating profit was $57.5M (5.1% of revenue) and net earnings $251M.